Literature DB >> 20522008

Unraveling the complexity of amyotrophic lateral sclerosis: recent advances from the transgenic mutant SOD1 mice.

M Peviani1, I Caron, C Pizzasegola, F Gensano, M Tortarolo, C Bendotti.   

Abstract

Amyotrophic Lateral Sclerosis (ALS), which accounts for the majority of motor neuron disorders, is a progressive and fatal neurodegenerative disease leading to complete paralysis of skeletal muscles and premature death usually from respiratory failure. About 10% of all ALS cases are inherited, with the responsible gene having been identified in approximately 25% of these individuals. Mutations in the copper-zinc superoxide dismutase (SOD1) gene were the first to be recognized nearly twenty years ago, and since then different animal models, in particular transgenic rodents, have been developed. They replicate many of the clinical, neuropathological and molecular features of ALS patients and have contributed significantly to our understanding of the pathogenic mechanisms of this disease. Although results obtained so far with mutant SOD1 mice have not translated into effective therapies in ALS patients, these models still represent the only experimentally accessible system to study multiple aspects of disease pathogenesis and to provide proof-of-principle for the development of new therapeutic strategies. This review will examine the most recent discoveries obtained from these animal models in an attempt to elucidate the complex mechanisms of the disease. In particular it will focus on the contribution of multiple cell types in governing the disease development and progression.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20522008     DOI: 10.2174/187152710791556096

Source DB:  PubMed          Journal:  CNS Neurol Disord Drug Targets        ISSN: 1871-5273            Impact factor:   4.388


  11 in total

Review 1.  Altered expression of atypical PKC and Ryk in the spinal cord of a mouse model of amyotrophic lateral sclerosis.

Authors:  Anna Tury; Kristine Tolentino; Yimin Zou
Journal:  Dev Neurobiol       Date:  2014-01-22       Impact factor: 3.964

Review 2.  Therapeutic neuroprotective agents for amyotrophic lateral sclerosis.

Authors:  Rachna S Pandya; Haining Zhu; Wei Li; Robert Bowser; Robert M Friedlander; Xin Wang
Journal:  Cell Mol Life Sci       Date:  2013-07-18       Impact factor: 9.261

3.  The omega-3 fatty acid eicosapentaenoic acid accelerates disease progression in a model of amyotrophic lateral sclerosis.

Authors:  Ping K Yip; Chiara Pizzasegola; Stacy Gladman; Maria Luigia Biggio; Marianna Marino; Maduka Jayasinghe; Farhan Ullah; Simon C Dyall; Andrea Malaspina; Caterina Bendotti; Adina Michael-Titus
Journal:  PLoS One       Date:  2013-04-19       Impact factor: 3.240

4.  Neuromuscular effects of G93A-SOD1 expression in zebrafish.

Authors:  Stacey A Sakowski; J Simon Lunn; Angela S Busta; Sang Su Oh; Grettel Zamora-Berridi; Madeline Palmer; Andrew A Rosenberg; Stephen G Philip; James J Dowling; Eva L Feldman
Journal:  Mol Neurodegener       Date:  2012-08-31       Impact factor: 14.195

5.  Alteration in superoxide dismutase 1 causes oxidative stress and p38 MAPK activation following RVFV infection.

Authors:  Aarthi Narayanan; Taissia Popova; Michael Turell; Jessica Kidd; Jessica Chertow; Serguei G Popov; Charles Bailey; Fatah Kashanchi; Kylene Kehn-Hall
Journal:  PLoS One       Date:  2011-05-31       Impact factor: 3.240

6.  Comparative Magnetic Resonance Imaging and Histopathological Correlates in Two SOD1 Transgenic Mouse Models of Amyotrophic Lateral Sclerosis.

Authors:  Ilaria Caron; Edoardo Micotti; Alessandra Paladini; Giuseppe Merlino; Laura Plebani; Gianluigi Forloni; Michel Modo; Caterina Bendotti
Journal:  PLoS One       Date:  2015-07-01       Impact factor: 3.240

7.  RNS60 exerts therapeutic effects in the SOD1 ALS mouse model through protective glia and peripheral nerve rescue.

Authors:  Antonio Vallarola; Francesca Sironi; Massimo Tortarolo; Noemi Gatto; Roberta De Gioia; Laura Pasetto; Massimiliano De Paola; Alessandro Mariani; Supurna Ghosh; Richard Watson; Andreas Kalmes; Valentina Bonetto; Caterina Bendotti
Journal:  J Neuroinflammation       Date:  2018-03-01       Impact factor: 8.322

8.  The pathological phenotypes of human TDP-43 transgenic mouse models are independent of downregulation of mouse Tdp-43.

Authors:  Ya-Fei Xu; Mercedes Prudencio; Jaime M Hubbard; Jimei Tong; Ena C Whitelaw; Karen Jansen-West; Caroline Stetler; Xiangkun Cao; John Song; Yong-Jie Zhang
Journal:  PLoS One       Date:  2013-07-26       Impact factor: 3.240

9.  Genetic background effects on disease onset and lifespan of the mutant dynactin p150Glued mouse model of motor neuron disease.

Authors:  Terry D Heiman-Patterson; Elizabeth P Blankenhorn; Roger B Sher; Juliann Jiang; Priscilla Welsh; Meredith C Dixon; Jeremy I Jeffrey; Philip Wong; Gregory A Cox; Guillermo M Alexander
Journal:  PLoS One       Date:  2015-03-12       Impact factor: 3.240

Review 10.  Major Histocompatibility Complex I Expression by Motor Neurons and Its Implication in Amyotrophic Lateral Sclerosis.

Authors:  Giovanni Nardo; Maria Chiara Trolese; Caterina Bendotti
Journal:  Front Neurol       Date:  2016-06-13       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.